Rx Hydroquinone Skin Bleach Regulatory Controls Sought By Galderma
This article was originally published in The Tan Sheet
Executive Summary
Galderma Labs calls for stricter FDA enforcement over marketing of unapproved prescription drugs and new requirements for disclosure regarding the lack of approval in recent comments to the agency
You may also be interested in...
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands